Rapid Regression of Choroidal Metastasis under First-Line Osimertinib Therapy in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Case Report
Case Reports in Ophthalmology · 2026-09-07 · 17 (1) · 980-987
DOI: 10.1159/cop/acaag008 ↗Abstract
Introduction: Choroidal metastases may cause substantial visual impairment in patients with metastatic non-small cell lung cancer (NSCLC). Although local ocular treatments are frequently considered, targeted systemic therapy may provide effective control in tumors harboring actionable mutations. We report the rapid regression of a choroidal metastasis following first-line osimertinib therapy in a patient with epidermal growth factor receptor (EGFR)-mutated NSCLC. Case Presentation: A 59-year-old man with metastatic EGFR-mutated NSCLC presented with progressive visual decline in the left eye. Ophthalmic examination revealed a peripapillary choroidal lesion associated with serous retinal detachment. Optical coherence tomography demonstrated subretinal fluid, consistent with a choroidal metastasis. First-line osimertinib therapy had been initiated 12 days before presentation at our clinic. An early reduction in subretinal fluid was observed during follow-up, followed by complete resolution at the 2-month follow-up. This was accompanied by regression of the choroidal lesion and improvement in visual function. No local ocular treatment was required. Conclusion: First-line osimertinib may induce rapid regression of choroidal metastases in patients with EGFR-mutated NSCLC. In selected cases, an early response to systemic targeted therapy may allow local ocular treatment to be avoided.
EUVIMED